Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetic profile of midazolam given alone
and midazolam given after multiple oral doses of 40 mg ridaforolimus.
Part 1 of this study is designed for evaluating CYP3A4 activity following 5 days of dosing of
ridaforolimus and is not designed with efficacy endpoints. Part 2 is a compassionate-use
extension to give patients an opportunity to receive a clinically active dose of
ridaforolimus. Part 2 dosing is open ended with limited data collection.